<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">1739628</article-id><article-id pub-id-type="pmc">1977739</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Philip</surname><given-names>P. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Joel</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Monkman</surname><given-names>S. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dolega-Ossowski</surname><given-names>E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tonkin</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Carmichael</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Idle</surname><given-names>J. R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Harris</surname><given-names>A. L.</given-names></name></contrib></contrib-group><aff>ICRF Clinical Oncology Unit, Churchill Hospital, Oxford, UK.</aff><pub-date pub-type="ppub"><month>2</month><year>1992</year></pub-date><volume>65</volume><issue>2</issue><fpage>267</fpage><lpage>270</lpage><abstract><p>Multidrug resistance (MDR) is one of the mechanisms of resistance to multiple cytotoxic drugs and is mediated by the expression of a membrane pump called the P-glycoprotein. Nifedipine is one of the calcium channel blocking agents which reverses MDR in vitro. Fifteen patients with various malignancies received nifedipine at three dose levels: 40 mg, 60 mg and 80 mg orally twice daily for 6 days. Etoposide was administered intravenously on day 2 in a dose of 150-250 mg m-2 and orally 150-300 mg twice daily on days 3 and 4. Cardiovascular effects of nifedipine were dose limiting and the maximum tolerated dose was 60 mg bid. Mean area under the plasma concentration curve (AUC0-00) and plasma half-life (beta) of nifedipine and its major metabolite MI at the highest dose level were 7.87 microM.h, 7.97 h and 4.97 microM.h, 14.0 h respectively. Nifedipine did not interfere with the pharmacokinetics of etoposide.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00066-0129.tif" xlink:title="scanned-page" xlink:role="267" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00066-0130.tif" xlink:title="scanned-page" xlink:role="268" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00066-0131.tif" xlink:title="scanned-page" xlink:role="269" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00066-0132.tif" xlink:title="scanned-page" xlink:role="270" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

